NCT03602612 2026-02-25
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT02659943 2023-04-19
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02664363 2023-02-17
ExCeL
Duke University
Phase 1 Terminated
NCT03049449 2023-01-18
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04160195 2022-02-15
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03958656 2021-09-09
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02215967 2019-10-08
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed